NCAM1 and neoplasm: Single cell analysis with imaging mass cytometry of samples from the neoTRIPaPDL1 clinical trial allowed the characterization of specific tumor microenvironment phenotypes, and revealed a predictive role of PD-L1+ indoleamine 2,3-dioxigenase+ APCs and CD56+ neuroendocrine epithelial cells [103].